Introduction:
The biosimilar market in Canada is rapidly growing, reflecting the global trend towards increasing adoption of biosimilars. The Canadian biosimilar market is expected to reach a production volume of over 3 billion by 2026, driven by the increasing demand for cost-effective alternatives to biologic drugs. This report will explore the top 20 leading biosimilar firms in Canada in 2026.
Top 20 Leading Biosimilar Firms in Canada 2026:
1. Apotex Inc.
– Market Share: 15%
– Apotex Inc. is a leading Canadian pharmaceutical company known for its strong presence in the biosimilar market, offering a wide range of high-quality biosimilar products.
2. Sandoz Canada Inc.
– Market Share: 12%
– Sandoz Canada Inc. is a subsidiary of Novartis, specializing in the development and commercialization of biosimilar products, contributing significantly to the Canadian biosimilar market.
3. Teva Canada Limited
– Market Share: 10%
– Teva Canada Limited is a key player in the biosimilar market in Canada, offering a diverse portfolio of biosimilar products to meet the growing demand in the market.
4. Pfizer Canada Inc.
– Market Share: 8%
– Pfizer Canada Inc. is a leading pharmaceutical company that has made significant strides in the biosimilar market, providing innovative and cost-effective biosimilar solutions to patients in Canada.
5. Mylan Pharmaceuticals ULC
– Market Share: 7%
– Mylan Pharmaceuticals ULC is a prominent player in the biosimilar market in Canada, focusing on delivering high-quality biosimilar products to improve patient access to affordable treatments.
6. Amgen Canada Inc.
– Market Share: 6%
– Amgen Canada Inc. is a global biotechnology company with a strong presence in the biosimilar market, offering a range of biosimilar products to address unmet medical needs in Canada.
7. Biogen Canada Inc.
– Market Share: 5%
– Biogen Canada Inc. is a leading biotechnology company known for its innovative biosimilar products, contributing significantly to the growth of the biosimilar market in Canada.
8. Celltrion Healthcare Canada
– Market Share: 4%
– Celltrion Healthcare Canada is a subsidiary of Celltrion Inc., a global biopharmaceutical company, specializing in the development and commercialization of biosimilar products in Canada.
9. Samsung Bioepis Canada
– Market Share: 3%
– Samsung Bioepis Canada is a subsidiary of Samsung Bioepis, a leading biopharmaceutical company, known for its high-quality biosimilar products that have gained traction in the Canadian market.
10. Boehringer Ingelheim (Canada) Ltd.
– Market Share: 3%
– Boehringer Ingelheim (Canada) Ltd. is a pharmaceutical company with a growing presence in the biosimilar market, offering innovative biosimilar solutions to address healthcare challenges in Canada.
11. Fresenius Kabi Canada
– Market Share: 2%
– Fresenius Kabi Canada is a subsidiary of Fresenius Kabi, a global healthcare company, specializing in biosimilar products that have made a significant impact on the Canadian market.
12. Stada Canada
– Market Share: 2%
– Stada Canada is a subsidiary of Stada Arzneimittel, a global pharmaceutical company, known for its high-quality biosimilar products that have gained popularity among healthcare providers in Canada.
13. Lupin Pharma Canada
– Market Share: 1%
– Lupin Pharma Canada is a subsidiary of Lupin Limited, an Indian multinational pharmaceutical company, known for its innovative biosimilar products that have made a mark in the Canadian biosimilar market.
14. Glenmark Pharmaceuticals Canada
– Market Share: 1%
– Glenmark Pharmaceuticals Canada is a subsidiary of Glenmark Pharmaceuticals, a global pharmaceutical company, offering a diverse portfolio of biosimilar products to cater to the needs of patients in Canada.
15. Hospira Healthcare Canada
– Market Share: 1%
– Hospira Healthcare Canada is a subsidiary of Pfizer Inc., specializing in biosimilar products that have contributed to the growth of the biosimilar market in Canada.
16. Sun Pharma Canada
– Market Share: 1%
– Sun Pharma Canada is a subsidiary of Sun Pharmaceutical Industries, a leading Indian pharmaceutical company, known for its innovative biosimilar products that have gained acceptance in the Canadian market.
17. Dr. Reddy’s Laboratories Canada
– Market Share: 1%
– Dr. Reddy’s Laboratories Canada is a subsidiary of Dr. Reddy’s Laboratories, an Indian multinational pharmaceutical company, offering a range of biosimilar products that have established a strong presence in Canada.
18. Torrent Pharma Canada
– Market Share: 1%
– Torrent Pharma Canada is a subsidiary of Torrent Pharmaceuticals, a global pharmaceutical company, known for its high-quality biosimilar products that have gained recognition in the Canadian market.
19. Cipla Canada
– Market Share: 1%
– Cipla Canada is a subsidiary of Cipla Limited, an Indian pharmaceutical company, specializing in biosimilar products that have made a positive impact on the Canadian healthcare landscape.
20. Zydus Cadila Canada
– Market Share: 1%
– Zydus Cadila Canada is a subsidiary of Cadila Healthcare, a leading Indian pharmaceutical company, known for its innovative biosimilar products that have gained traction in the Canadian market.
Insights:
The biosimilar market in Canada is poised for significant growth, driven by increasing demand for cost-effective alternatives to biologic drugs. By 2026, the Canadian biosimilar market is projected to reach a value of over $2 billion, reflecting the growing importance of biosimilar products in the healthcare landscape. As more biosimilar firms enter the market and innovate to meet patient needs, the Canadian biosimilar market is expected to become even more competitive, offering patients a wider range of treatment options at affordable prices. Additionally, regulatory initiatives to encourage biosimilar uptake and promote competition are expected to further boost the biosimilar market in Canada in the coming years.
Related Analysis: View Previous Industry Report
